The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes Across a Wide Range of Concentrations

PURPOSE: PLX4032 (RG7204), an oncogenic BRAF kinase inhibitor undergoing clinical evaluation, has high response rates in early clinical trials in patients with advanced BRAF(V600E) mutant melanoma. Combining PLX4032 with immunotherapy may allow expanding the durability of responses. The effects of P...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Comin-Anduix, Begoña, Chodon, Thinle, Sazegar, Hooman, Matsunaga, Douglas, Mock, Stephen, Jalil, Jason, Escuin-Ordinas, Helena, Chmielowski, Bartosz, Koya, Richard C., Ribas, Antoni
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057460/
https://ncbi.nlm.nih.gov/pubmed/21169256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1911
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi